Umifenovir Lipodisq Sterile Solution
| Code | Size | Price |
|---|
| IAX-700-106-L001 | 1 ml | £197.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
AMBIENT
Storage:
Short term: +4°C. Long term: -20°C
Documents
Further Information
Alternate Names/Synonyms:
Arbidol; ARB
Appearance:
Light yellow coloured clear aqueous solution
Biological Activity:
Discoidal nano-particles can incorporate hydrophobic, poorly water-soluble compounds, such as lipids, lipoproteins and glycolipids. - Cell culture tested (human macrophage cell line) (MTT). - Recommended starting dilution: 1:200 or higher. - Optimal working concentrations depend on the applications and need to be determined. - Published procedures using Lipodisq formulations (Curcumin and IAXO TLR4 antagonists) in vivo rodent models at 3-10mg/kg. Recommended route of administration is subcutaneous (s.c.) with oral or nasal application as a possible alternative, which needs to be optimized.
CAS:
131707-23-8
Concentration:
1mg/ml (0.1% w/vol)
EClass:
32160000
Form (Short):
liquid
Formulation:
Liquid, detergent-free discoidal nano-formulation made of styrene-maleic acid lipid particles (SMALP), lecithin and sterile water.
GHS Symbol:
GHS07
Handling Advice:
Keep sterile. Avoid skin and eye contact.
Hazards:
H315, H319
InChi:
S/C22H25BrN2O3S.ClH/c1-5-28-22(27)20-18(13-29-14-9-7-6-8-10-14)25(4)17-11-16(23)21(26)15(19(17)20)12-24(2)3;/h6-11,26H,5,12-13H2,1-4H3;1H
InChiKey:
OMZHXQXQJGCSKN-UHFFFAOYSA-N
Long Description:
Chemical. CAS: 131707-23-8. Formula: C22H25BrN2O3S . HCl. MW: 477.4 . 36.5. Umifenovir Lipodisq Sterile Solution is a ready-to-use nano-formulated aqueous solution. Umifenovir (Arbidol) is known to have broad-spectrum anti-viral activity and has earlier been approved in China and Russia for treating influenza, SARS, and Lassa viruses. It has been tested in multiple clinical studies as a candidate for use as an anti-COVID19 therapeutic and has been suggested to act at the entry stage and at the post-entry stages by preventing viral attachment and inhibiting the release of virus particles from intracellular vesicles, respectively. In a recent phase III, clinical study Umifenovir met the primary and secondary endpoint criteria. It has been shown to efficacious, safe and well-tolerated at the tested dosage. Umifenovir Lipodisq is based on a nanoparticle (11-40nm) drug delivery system comprising a discoidal phospholipid bilayer membrane stabilized by a chaperone molecule annulus. Internal properties of the phospholipid membrane support the disposition and stabilization of drug molecule candidates and preserve the native conformation of membrane molecules. The resulting encapsulated actives are rendered water-soluble and specialized for intra-cellular penetration/delivery via endosomal uptake mechanisms. Lipodisq solutions show a good safety profile and are suitable for in vitro and in vivo investigations.
MDL:
MFCD00344795
Molecular Formula:
C22H25BrN2O3S . HCl
Molecular Weight:
477.4 . 36.5
Other data:
Lipodisq™ technology is covered by one or more of the following patents owned by Malvern Cosmeceutics Limited: AU2006253886, CA2611144, CN101184473B, EP1890675, GB2426703, IN261468, JP5142898, US8623414 and WO/2021/005340A1 pending. The purchaser is licensed under those patents to use these assemblies for the purpose of research and development only, but not for the purpose of delivery of agents for clinical use to humans or veterinary use to animals for therapeutic, diagnostic or prophylactic purposes, which uses are specifically prohibited.
Package Type:
Vial
Precautions:
P302+P352, P305+351+338
Product Description:
Umifenovir Lipodisq Sterile Solution is a ready-to-use nano-formulated aqueous solution. Umifenovir (Arbidol) is known to have broad-spectrum anti-viral activity and has earlier been approved in China and Russia for treating influenza, SARS, and Lassa viruses. It has been tested in multiple clinical studies as a candidate for use as an anti-COVID19 therapeutic and has been suggested to act at the entry stage and at the post-entry stages by preventing viral attachment and inhibiting the release of virus particles from intracellular vesicles, respectively. In a recent phase III, clinical study Umifenovir met the primary and secondary endpoint criteria. It has been shown to efficacious, safe and well-tolerated at the tested dosage. Umifenovir Lipodisq is based on a nanoparticle (11-40nm) drug delivery system comprising a discoidal phospholipid bilayer membrane stabilized by a chaperone molecule annulus. Internal properties of the phospholipid membrane support the disposition and stabilization of drug molecule candidates and preserve the native conformation of membrane molecules. The resulting encapsulated actives are rendered water-soluble and specialized for intra-cellular penetration/delivery via endosomal uptake mechanisms. Lipodisq solutions show a good safety profile and are suitable for in vitro and in vivo investigations.
Purity:
>95% (HPLC)
Signal Word:
Warning
SMILES:
BrC1=C(O)C(CN(C)C)=C(C(C(OCC)=O)=C(CSC2=CC=CC=C2)N3C)C3=C1.Cl
Solubility Chemicals:
Soluble in water, PBS, Tris and other physiological solutions as formulated in a proprietary, thermostable, aqueous lipid nanoparticulate formulation (Lipodisq).
Transportation:
Non-Hazardous
UNSPSC Category:
Biochemical Reagents
UNSPSC Number:
12352200
Use & Stability:
Stable for at least 1 year after receipt when stored at -20°C.
References
Arbidol: A broad-spectrum antiviral compound that blocks viral fusion: Y.S. Boriskin, et al.; Curr. Med. Chem. 15, 997 (2008) (Review) | Arbidol as a broad-spectrum antiviral: an update: J. Blaising, et al.; Antiviral Res. 107, 84 (2014) (Review) | Potential treatment methods targeting 2019-nCoV infection: L.U. Zheng, et al.; Eur. J. Med. Chem. 205, 112687 (2020) | Phase III, Randomized, Double-blind, Placebo controlled trial of Efficacy, Safety and Tolerability of Antiviral drug Umifenovir vs Standard care of therapy in non-severe COVID-19 patients: R. Ramachandran, et al.; Int. J. Infect. Dis. 115, 62 (2022) | General References for Lipodisq™ Technology: | Responsive Hydrophobically Associating Polymers: A Review of Structure and Properties: S.R. Tonge & B.J. Tighe; Adv. Drug Deliv. Rev. 53, 109 (2001) | Detergent-free formation and physico-chemical characterization of nanosized lipidpolymer complexes: Lipodisq; M.C. Orwick, et al.; Angew. Chem. 51, 4653 (2012) | Physicochemical Characterization, Toxicity and In Vivo Biodistribution Studies of a Discoidal, Lipid-Based Drug Delivery Vehicle: Lipodisq Nanoparticles Containing Doxorubicin: M.L. Torgersen, et al.; J. Biomed. Nanotechnol. 16, 41 (2020) | Applications of Synthetic Polymer Discoidal Lipid Nanoparticles to Biomedical Research: M. Tanaka; Chem. Pharm. Bull. 70, 507 (2022) | Mechanisms of Formation, Structure, and Dynamics of Lipoprotein Discs Stabilized by Amphiphilic Copolymers: A Comprehensive Review: P.S. Orekhov, et al.; Nanomaterials 12, 361 (2022)